Table 6. DRI values for clonogenic cell killing by RG7388/Nutlin-3 in combination with cisplatin in wild-type TP53 ovarian cancer cell lines.
| Cell Line | Combination | Component | DRI | ||||
|---|---|---|---|---|---|---|---|
| XGI50 | |||||||
| 0.25 | 0.5 | 1 | 2 | 4 | |||
| A2780 | Nut-3+CDDP | Nut-3 | 1.3 | 7.3 | 10.7 | 7.8 | 10.9 |
| CDDP | 2.1 | 4.0 | 3.4 | 2.2 | 2.0 | ||
| RG+CDDP | RG7388 | 1.6 | 1.9 | 2.0 | 2.5 | 3.5 | |
| CDDP | 3.2 | 2.6 | 2.1 | 1.8 | 1.7 | ||
| IGROV-1 | Nut-3+CDDP | Nut-3 | 6.4 | 5.4 | 4.1 | ND | ND |
| CDDP | 5.1 | 3.7 | 2.2 | ND | ND | ||
| RG+CDDP | RG7388 | 4.3 | 4.3 | 4.3 | 4.5 | 11.0 | |
| CDDP | 2.1 | 1.4 | 0.9 | 0.6 | 0.6 | ||
| OAW42 | Nut-3+CDDP | Nut-3 | 1.6 | 1.5 | 1.3 | ND | ND |
| CDDP | 1.8 | 3.2 | 5.0 | ND | ND | ||
| RG+CDDP | RG7388 | 1.0 | 1.1 | 1.2 | 1.4 | 2.0 | |
| CDDP | 2.1 | 1.7 | 1.4 | 1.1 | 0.9 | ||
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective LC50 concentrations. DRI values were calculated for each constant ratio combination from the average of at least three independent experiments. Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; DRI, Dose Reduction Index; ND; Not determined; Favorable DRI values are highlighted in bold font.